Meggan Mackay
Rheumatology · Manhasset, NYNPI 1164542197
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (49.2%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 5 manufacturers reported payments, led by E.r. Squibb & Sons, L.L.C. at 40.8% of the total. Reporting peaked in 2021 at $3,260 and has fallen 99.4% since, to $20 in 2022.
Across 12 payments — averaging $596.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- E.r. Squibb & Sons, L.L.C.$3K
- Aurinia Pharma U.S., Inc.$3K
- Eli Lilly$958
- AbbVie$600
- GSK$20
Across 153 payments — averaging $9394.90 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$366K
- E.r. Squibb & Sons, L.L.C.$302K
- Eli Lilly$238K
- Astrazeneca UK Limited$226K
- AstraZeneca$148K
- Janssen Research & Development, LLC$57K
- plus $100K from 5 others
What the payments were for
- Consulting fees$3,52549%
- Speaking & faculty fees$2,52035%
- Travel & lodging$83512%
- Food & beverage$2834%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| E.r. Squibb & Sons, L.L.C. | 2 | $2,925 |
| Aurinia Pharma U.S., Inc. | 2 | $2,660 |
| Eli Lilly | 6 | $958 |
| AbbVie | 1 | $600 |
| GSK | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,163 in reported general payments places this provider in the 65th percentile of 541 rheumatology providers in New York.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BenlystaBelimumab | 47 | $214,781 |
| Mycophenolic AcidMycophenolate Sodium | 18 | $8,051 |
| Hydroxychloroquine Sulfate | 171 | $4,247 |
| Mycophenolate Mofetil | 31 | $2,770 |
| Leflunomide | 33 | $780 |
| ValacyclovirValacyclovir Hcl | 14 | $632 |
| Clobetasol Propionate | 11 | $480 |
| Metoprolol Succinate | 20 | $408 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 13 | $407 |
| Prednisone | 72 | $341 |
| Ibuprofen | 31 | $282 |
| Nifedipine ErNifedipine | 12 | $264 |
| MethotrexateMethotrexate Sodium | 14 | $189 |
| Lisinopril | 18 | $141 |
| Tramadol Hcl | 12 | $117 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKBenlysta | $20 | $214,78147 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 541 rheumatology providers in New York.
Other rheumatology in Manhasset
- Cynthia AranowManhasset$59K
- Laurie GlimcherNew York$3.9M
- Grace WrightNew York$3M
- Kostas BotsoglouCheektowaga$2.6M
- Sergio SchwartzmanNew York$2.5M
- Allan GibofskyNew York$1.9M
- Petros EfthimiouNew York$791K
- Richard FurieNew Hyde Park$746K
- Barry GruberBabylon$742K
- Olga PetrynaNew York$509K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.